Combined use of plasmid drug pCMV-VEGFA and autodermoplasty for stimulation of skin defects healing in the experiment

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


To find effective ways to stimulate chronic skin wounds healing (including deep burns, diabetic and trophic ulcers) is an actual multidisciplinary task. The aim of our study was to assess the potential of using autodermoplasty in combination with plasmid drug pCMV-VEGFA to optimize skin defects repair in the experiment. Autodermoplasty was performed on Wistar rats. The size of the skin flap was 2x2 cm. Immediately after surgery the animals of the test group (n=8) underwent intradermal injection in the periphery of autotransplant with 1 ml solution containing 0.3 mg of supercoiled plasmid DNA pCMV-VEGFA, rats of the control group (n=8) received 1 ml of 0.9 % NaCl. The results were analyzed in 3, 6, 9 12, 18 days using macroscopic evaluation, laser Doppler flowmetry, histological methods. Macroscopically in the test group necrosis of the transplanted skin flap was found at later periods of observation, in one case complete survival of autotransplant was observed. The results of laser Doppler flowmetry in the group with plasmid DNA did not have statistically significant differences with control. The wound defect diameter in the test group at 12 days was 5,52± 4.80 mm, in the control - 12,45±0,82 mm (p=0,03); 2,53±of 2,94 mm and 4,23±3,5 mm (p=0,067) at 18 days, respectively. At 18 days, the average number of vessels under the flap in the central zone were: of 26±2,9 in the test group and 20±8 - in control; it the peripheral zone - 27±3,4 and of 12,1±3,9 (p=0,035), respectively; in the skin muscle - 21,2±of 3,9 and 12,4±3,6 (p=0,04), respectively. Thus, the use of plasmid drug pCMV-VEGFA improved the skin healing after autodermoplasty.

Full Text

Restricted Access

About the authors

A. I Bilialov

Kazan (Volga region) Federal University


M. S Abyzova

Kazan State Medical University

A. A Titova

Kazan (Volga region) Federal University

M. O Mavlikeev

Kazan (Volga region) Federal University

AA. Krilov

Ryazan State Medical University

I. Y Bozo

Human Stem Cell Institute; Federal Medical Biophysical Center, FMBA of Russia

R. V Deev

Ryazan State Medical University; Human Stem Cell Institute


  1. Andrews K.L., Houdek M, Kiemele L. Wound management of chronic diabetic foot ulcers: from the basics to regenerative medicine. Prosthet. Orthot. Int. 2015; 39(I): 29-39.
  2. Kim H.S., Yoo H. In vitro and in vivo epidermal growth factor gene therapy for diabetic ulcers with electrospun fibrous meshes. Acta. Biomater. 2013; 9(VII): 7371-80.
  3. Александрова Г.А., Поликарпов А., Голубев Н. и др. Заболеваемость всего населения России в 2016 году. Статистические материалы. Министерство здравоохранения Российской Федерации. Департамент мониторинга, анализа и стратегического развития здравоохранения. ФГБУ «Центральный научно-исследовательский институт организации и информатизации здравоохранения» Минздрава России. 2017; 25-100.
  4. Global report on diabetes. Geneva: World Health Organization, 2016; 34-42.
  5. Lal B.K. Venous ulcers of the lower extremity: definition, epidemiology, and economic and social burdens. Semin. Vasc. Surg. 2015; 28(I): 3-5.
  6. Тюрников Ю.Р., Евтеев А., Малютина Н. Комплексный анализ летальности по ожоговому стационару за 22-летний период. III съезд комбустиологов России. Тезисы докладов, 2010; 36-7.
  7. Weledji E.P., Fokam P. Treatment of the diabetic foot-to amputate or not? BMC Surg. 2014; 83-7.
  8. Галстян Г.Р., Токмакова А. Клинические рекомендации по диагностике и лечению синдрома диабетической стопы. Раны и раневые инфекции. Журнал имени проф. Б.М. Костючёнка 2015; 2(III): 63-83.
  9. Шапкин Ю.Г. Способ повышения эффективности пластического закрытия ран после отморожения. Анналы хирургии. 2010; 5: 72-5.
  10. Alexiadou K.I., Doupis J. Management of diabetic foot ulcers. Diabetes Ther. 2012; 3: 4-6.
  11. Kang N.R., Hai Y, Liang F et al. Preconditioned hyperbaric oxygenation protects skin flap grafts in rats against ischemia/reperfusion injury. Mol. Med. Report. 2014; 9(VI): 2124-30.
  12. Парфенова Е.В., Ткачук В.А. Терапевтический ангиогенез: достижения, проблемы, перспективы. Кардиологический вестник 2007; 2: 5-15.
  13. Mao A.S., Mooney D. Regenerative medicine: current therapies and future directions. Proc. Natl. Acad. Sci. 2015; 112: 14452-59.
  14. Talebi M.I., Palizban A. Viral and nonviral delivery systems for gene delivery. Adv. Biomed. Res. 2012; 1: 27-30.
  15. Martino M.M., Tortelli F., Mochizuki M. et al. Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. Sci. Transl. Med. 2011; 3: 20-5.
  16. Mayer H.L., Bertram H., Lindenmaier W. et al. Vascular endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: autocrine and paracrine role on osteoblastic and endothelial differentiation. J. Cell Biochem. 2005; 2: 30-34.
  17. Detmar M.A. The role of VEGF and thrombospondins in skin angiogenesis. Dermatol. Sci. 2000; 24: 78-84.
  18. Eckhart L.F. Cell death by cornification. Biochim. Biophys. Acta. 2013; 18: 34-45.
  19. Martino M.M., Brkic S., Bovo E. et al. Extracellular matrix and growth factor engineering for controlled angiogenesis in regenerative medicine. Front. Bioeng. Biotechnol. 2015; 4: 45-60.
  20. Martino M.M., Tortelli F., Mochizuki M. et al. Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. Sci. Transl. Med. 2011; 1: 20-5.
  21. Kenna C.C., Ojeda A., Spurlin J. Sema3A maintains corneal avascularity during development by inhibiting Vegf induced angioblast migration. Dev. Biol. 2013; 10-5.
  22. Gould S.J., Subramani S. Firefly luciferase as a tool in molecular and cell biology. Analytical Biochemistry. 1988; 175(I): 5-13.
  23. Гуманенко Е.К. Военно-полевая хирургия учебник. 2-е изд., испр. и доп. М.: ГЭОТАР-Медиа. 2015.

Copyright (c) 2018 Eco-Vector

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 85657 от 21.07.2023 от 11.03.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies